“UAE has one of the highest prevalence rates of diabetes in the world, ranking 10th globally, so to be able to provide another treatment option will not only support the growing number of UAE diabetics in reducing their glucose levels, but also ensure that their levels of ‘bad cholesterol’ are kept in check, which is extremely important,” said Dr. Mazen Altaruti, Managing Director of MSD in the Gulf.
“Clinical guidelines consider people with diabetes as having a similar cardiovascular risk as those with coronary heart disease. Despite the fact that cardiovascular disease is the leading complication resulting in death amongst Type 2 diabetics. According to studies commissioned by MSD in the Middle East, only around 20% of patients advised to take statin therapies, actually d,. he added.”
“At MSD we are constantly striving to provide innovative pharmaceutical solutions that make getting healthy and staying healthier as easy as possible for patients, and we truly believe this combination therapy, will do just that”, he concluded.
Dr. Ahmed Al-Jebawi, Consultant Endocrinologist and Chairman of the Advanced Diabetes Training Programme at the Dubai Diabetes Centre, said, “One of the major reasons for the increasing number of type 2 diabetics in the UAE market is lifestyle.”
“Sedentary life, lack of physical activity and poor dietary choices are major factors in the growing prevalence of type 2 diabetes. If we are to truly start addressing this epidemic we need to work more closely with our patients to ensure that they are properly counselled on the need to manage their lifestyle in combination with the correct medical regimen,” he added.
Juvicor is a combination of two well-known, effective, medications: blood sugar lowering Januvia (sitagliptin), and the cholesterol-lowering medication ZOCOR (simvastatin), in a single, convenient, once-daily tablet.
Talking about how the treatment will work and the ways in which it can support type 2 diabetics, Dr. Omar Hallak, Chief of the Interventional Cardiology Department at the American Hospital in Dubai, explains, “The treatment combines sitagliptin, the most dispensed DPP-4 inhibitor in the world, which works by enhancing the body’s natural response system, to help regulate blood sugar by increasing levels of active GLP-1 and GIP hormones. Simvastatin is a cholesterol lowering medication that works to lower, low-density lipoproteins, or ‘bad’ cholesterol, in combination with diet and lifestyle management. The combination is particularly important since studies have shown that cholesterol levels in diabetics with uncontrolled sugar levels are far higher. Over time, persistent levels of high blood sugar can lead to increased plaque buildup inside arteries, putting people with diabetes at higher risk for heart disease.”
The Ministry of Health in the UAE approved Juvicor, based upon clinical bioequivalence studies in healthy subjects that demonstrated administration of Juvicor is bioequivalent to co-administration of Januvia and ZOCOR as individual tablets.
MSD is committed to further advancing the medical community’s understanding of how to better manage type 2 diabetes, and to providing novel treatment options to people with type 2 diabetes who need them. With Januvia and now Juvicor, MSD has a growing family of products that provides physicians with important treatment options for patients with type 2 diabetes.
Wednesday, November 7- 2012 @ 10:48 UAE local time (GMT+4) Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of Mediaquest FZ LLC.